Charles Schwab Investment Management Inc Inozyme Pharma, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 143,158 shares of INZY stock, worth $747,284. This represents 0.0% of its overall portfolio holdings.
Number of Shares
143,158
Previous 126,535
13.14%
Holding current value
$747,284
Previous $969,000
34.16%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding INZY
# of Institutions
92Shares Held
52.4MCall Options Held
17.6KPut Options Held
2.7K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.73MShares$29.9 Million0.05% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$23.5 Million18.06% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$22.3 Million1.06% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.94MShares$20.5 Million0.31% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.7MShares$19.3 Million0.51% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $210M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...